These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
3. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy. Singh SR; Sahoo NK; Goud NR; Chhablani J Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423 [TBL] [Abstract][Full Text] [Related]
9. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial. Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967 [TBL] [Abstract][Full Text] [Related]
10. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163 [TBL] [Abstract][Full Text] [Related]
11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
12. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study. Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity. Kim M; Jeong S; Sagong M Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671 [TBL] [Abstract][Full Text] [Related]
15. PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial. Nourinia R; Emamverdi M; Ramezani A; Amizadeh Y; Khorshidifar M; Behnaz N; Safi S Retina; 2020 Jun; 40(6):1110-1117. PubMed ID: 31157710 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. Son BK; Kwak HW; Kim ES; Yu SY Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106 [TBL] [Abstract][Full Text] [Related]
17. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema. Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Tomomatsu Y; Tomomatsu T; Takamura Y; Gozawa M; Arimura S; Takihara Y; Inatani M Acta Ophthalmol; 2016 May; 94(3):e225-30. PubMed ID: 25989706 [TBL] [Abstract][Full Text] [Related]
19. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia. Karasu B; Gunay BO Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680 [TBL] [Abstract][Full Text] [Related]
20. Impact of Early Anatomical and Functional Responses to Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. Noh D; Ryu G; Lee J; Sagong M Ophthalmologica; 2018; 239(4):194-204. PubMed ID: 29393235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]